Cwm LLC Has $132,000 Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Cwm LLC raised its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 59.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,342 shares of the company’s stock after acquiring an additional 3,105 shares during the quarter. Cwm LLC’s holdings in Mineralys Therapeutics were worth $132,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of Mineralys Therapeutics by 43.0% in the fourth quarter. Wellington Management Group LLP now owns 91,529 shares of the company’s stock worth $1,127,000 after buying an additional 27,531 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Mineralys Therapeutics in the 4th quarter valued at $202,000. GAMMA Investing LLC increased its holdings in Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock valued at $140,000 after buying an additional 8,738 shares during the period. BNP Paribas Financial Markets bought a new stake in Mineralys Therapeutics in the 4th quarter valued at $48,000. Finally, JPMorgan Chase & Co. increased its holdings in Mineralys Therapeutics by 2,251.5% in the 4th quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company’s stock valued at $6,199,000 after buying an additional 482,174 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Performance

NASDAQ MLYS opened at $13.88 on Wednesday. The business has a 50 day simple moving average of $14.65 and a 200 day simple moving average of $13.20. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38. The stock has a market cap of $904.70 million, a price-to-earnings ratio of -3.72 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23. On average, analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 11,366 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.59, for a total transaction of $165,829.94. Following the completion of the transaction, the insider owned 97,907 shares in the company, valued at approximately $1,428,463.13. This represents a 10.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 15,884 shares of the firm’s stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $14.51, for a total value of $230,476.84. Following the completion of the transaction, the chief executive officer owned 846,405 shares of the company’s stock, valued at approximately $12,281,336.55. This represents a 1.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,374 shares of company stock worth $725,546 over the last ninety days. Insiders own 33.24% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MLYS. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 14th. Finally, Jefferies Financial Group assumed coverage on shares of Mineralys Therapeutics in a research report on Tuesday, June 10th. They set a “hold” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $32.25.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.